Quarter to Sep 2026: consolidated revenue up 50%, after-tax profit up 30% year on year; revised
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026, revenue from operations was 4,708.40 lakh versus 3,133.70 lakh a year earlier, while profit after tax was 659.60 lakh versus 509.11 lakh. The revised half-year results regrouped borrowings and cash flow after a BSE query; balance-sheet and cash-flow totals and net profit were unchanged. Consolidated long-term borrowings fell to 5,445.20 lakh and short-term borrowings rose to 3,548.72 lakh.
The regrouping changes no results or total debt, but more borrowings now fall due soon, raising the need to repay or roll them over.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹80.80 Cr | ₹53.36 Cr | +51.4% |
| Operating profit | ₹13.87 Cr | ₹7.54 Cr | +84.0% |
| Profit after tax | — | — | — |
| EBITDA margin | — | — | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.